Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Johns Hopkins gene hunters pinpoint new cancer gene target


Scientists at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute have found mutations in a gene linked to the progression of colon and other cancers. The research findings, published online in the March 11 issue of Science, may lead to new therapies and diagnostic tests that target this gene.

The gene in which the mutations have been found, called PIK3CA, is part of a family of genes encoding lipid kinases, enzymes that modify fatty molecules and direct cells to grow, change shape and move. Although scientists have been studying the biochemical properties of this family of genes for more than a decade, until now, no study revealed that they were mutated in cancer.

Kinases have been the focus of recent drug development strategies, with some kinase-inhibiting compounds, such as Gleevec and Herceptin, already being used clinically to inhibit tumor growth.

"These findings open the door to developing specific therapies that may prove useful for the treatment of cancers with mutations in PIK3CA," says Victor Velculescu, M.D., Ph.D., assistant professor of oncology and senior author of the research.

In their current experiments, the scientists sequenced the molecular code of the genes in this lipid kinase family and found mistakes in the nucleotides, or DNA building blocks, in one particular gene, called PIK3CA. Each mistake is a result of one nucleotide being switched for another. PIK3CA mutations were found in 32 percent of colon cancer samples (74/234), as well as 27 percent (4/15) of glioblastomas, 25 percent (3/12) of gastric cancers, 8 percent (1/12) breast cancers and 4 percent (1/24) of lung cancers. By studying 76 additional premalignant colon tumors, the scientists found that PIK3CA mutations may occur at or near the time a tumor is about to invade other tissues.

The investigators demonstrated that the mutations increase PIK3CA kinase activity, which can start a cascade of cellular events that spark a normal cell to grow uncontrollably and become cancerous.

"We envision future cancer therapy as personalized, based on gene mutations in each patient’s tumor," says Velculescu. "This kind of information, gleaned from sequencing a patient’s tumor, means drugs could be targeted to just the right molecular pathway at just the right time and potentially be more effective with fewer side effects."

Most of the PIK3CA mutations described in the current paper are located in two DNA cancer "hot spots," thus making molecular diagnostic tests possibly easier to develop. "These mutations, added to a panel of existing markers for colon cancer developed in our laboratory, could help find cancers that would otherwise go undetected," says Yardena Samuels, Ph.D., postdoctoral fellow and first author of the study.

The researchers are now looking more closely at the role of PIK3CA in tumor development and are working on identifying compounds that could target tumors with mutations in this gene.

This research was funded by the Ludwig Trust, the Benjamin Baker Scholarship Fund, the EMBO Fellowship Fund and grants from the National Institutes of Health.

Other participants of this research include Zhenghe Wang, Alberto Bardelli, Natalie Silliman, Janine Ptak, Steve Szabo, Gregory J. Riggins, Kenneth W. Kinzler and Bert Vogelstein of the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute; Hai Yan of Duke University Medical Center; Adi Gazdar of UT Southwestern Medical Center; Steven M. Powell of the University of Virginia Health System; and James K.V. Willson and Sanford Markowitz of the Howard Hughes Medical Institute and Ireland Cancer Center, University Hospitals of Cleveland and Case Western University.

Vanessa Wasta | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>